Intaxel

• Paclitaxel Injection (INTAXEL) is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection is indicated in combination with cisplatin.
• Paclitaxel Injection (INTAXEL) is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
• Paclitaxel Injection (INTAXEL) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
• Paclitaxel Injection (INTAXEL) in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
• Paclitaxel Injection (INTAXEL) is indicated for the second-line treatment of AIDS- related Kaposi’s sarcoma.

• Intaxel - Paclitaxel 30 mg/5 ml
• Intaxel - Paclitaxel 100 mg/16.7 ml
• Intaxel - Paclitaxel 260mg/43.4 ml

All patients should be premedicated prior to INTAXEL administration in order to prevent severe hypersensitivity reactions. (See ‘Premedication Regimens’ below). 

• Ovarian Cancer:

For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks.

Paclitaxel administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2;

Paclitaxel administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2

In patients previously treated with chemotherapy for carcinoma of the ovary, paclitaxel Injection has been used at several doses and schedules; however, the optimal regimen is not yet clear. The recommended regimen is paclitaxel 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks.

• Breast Cancer:

For the adjuvant treatment of node-positive breast cancer, the recommended regimen is paclitaxel, at a dose of 175 mg/m2 intravenously over 3 hours every 3 weeks for four courses administered sequentially to doxorubicin-containing combination chemotherapy. The clinical trial used four courses of doxorubicin and cyclophosphamide.

After failure of initial chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, paclitaxel at a dose of 175 mg/m2 administered intravenously over 3 hours every 3 weeks has been shown to be effective.

• Non-Small Cell Lung Cancer:

For patients with non-small cell lung carcinoma, the recommended regimen, given every 3 weeks, is paclitaxel administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin, 75 mg/m2.

• AIDS-related Kaposi’s Sarcoma:

For patients with AIDS-related Kaposi’s sarcoma, paclitaxel administered at a dose of 135 mg/m2 given intravenously over 3 hours every 3 weeks or at a dose of 100 mg/m2 given intravenously over 3 hours every 2 weeks is recommended (dose intensity 45-50 mg/m2/week

• Paclitaxel Injection (Intaxel) is available as 30 mg/5ml, 100 mg/17ml and 260 mg/43.4 ml vials individually packaged in a carton.
• For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory